High compliance to ERAS protocol does not improve overall survival in patients treated for resectable advanced gastric cancer.
adherence
enhanced recovery after surgery
gastrectomy
gastric cancer
laparoscopy
Journal
Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques
ISSN: 1895-4588
Titre abrégé: Wideochir Inne Tech Maloinwazyjne
Pays: Poland
ID NLM: 101283175
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
19
11
2019
accepted:
04
01
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
ppublish
Résumé
The ERAS (Enhanced Recovery after Surgery) protocol revolutionized perioperative care for gastrointestinal surgical procedures. However, little is known about the association between adherence to the ERAS protocol in gastric cancer surgery and the oncological outcome. To explore the relation between adherence to the ERAS protocol and the oncological outcome in gastric cancer patients. We performed a retrospective analysis of a prospectively collected database of patients treated for gastric cancer between 2013 and 2016. All patients were treated perioperatively with a 14-item ERAS protocol. Every patient underwent regular follow-up every 3 months for 3 years after surgery. 80% compliance to the ERAS protocol was the goal during perioperative care. Based on the level of compliance, patients were divided into group 1 and group 2 (compliance of ≥ 80% and < 80%, respectively). Compliance to the ERAS protocol was not a risk factor for diminished overall survival - probability of 3-year survival was 63% in group 1 and 56% in group 2 (p = 0.75). The proportional Cox model revealed that only stage III gastric cancer was a risk factor of poor prognosis in patients operated on for gastric cancer (HR = 7.89, 95% CI: 2.96-20.89; p = 0.0001). High adherence to the ERAS protocol did not improve overall survival in our 3-year observation. Only the stage of the disease, according to the AJCC classification, was identified as a risk factor for poor prognosis.
Identifiants
pubmed: 33294069
doi: 10.5114/wiitm.2020.92833
pii: 39812
pmc: PMC7687667
doi:
Types de publication
Journal Article
Langues
eng
Pagination
553-559Informations de copyright
Copyright: © 2020 Fundacja Videochirurgii.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Wideochir Inne Tech Maloinwazyjne. 2017;12(1):7-12
pubmed: 28446926
World J Gastroenterol. 2015 Jun 28;21(24):7343-8
pubmed: 26139980
Eur J Surg Oncol. 2017 Aug;43(8):1433-1439
pubmed: 28528188
Wideochir Inne Tech Maloinwazyjne. 2018 Sep;13(3):326-332
pubmed: 30302145
Wideochir Inne Tech Maloinwazyjne. 2018 Dec;13(4):442-447
pubmed: 30524613
J Thorac Dis. 2017 Jul;9(Suppl 8):S781-S784
pubmed: 28815074
Obes Surg. 2019 Feb;29(2):492-498
pubmed: 30443718
J Thorac Dis. 2019 Apr;11(Suppl 5):S685-S691
pubmed: 31080645
World J Surg Oncol. 2018 Jan 26;16(1):17
pubmed: 29373978
World J Surg. 2016 Jul;40(7):1741-7
pubmed: 26913728
Ann Surg. 2018 Jun;267(6):992-997
pubmed: 29303803
Wideochir Inne Tech Maloinwazyjne. 2014 Mar;9(1):13-7
pubmed: 24729804
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Br J Surg. 2014 Sep;101(10):1209-29
pubmed: 25047143
Clin Nutr. 2012 Dec;31(6):801-16
pubmed: 23062720
World J Surg. 2019 Mar;43(3):659-695
pubmed: 30426190
Dis Colon Rectum. 2017 Aug;60(8):761-784
pubmed: 28682962
Adv Med Sci. 2016 Sep;61(2):306-310
pubmed: 27152766
Ann Surg. 2018 Jun;267(6):998-999
pubmed: 29462010
Surg Endosc. 2020 May;34(5):2067-2075
pubmed: 31385073
Int J Surg. 2015 Sep;21:75-81
pubmed: 26231994
Wideochir Inne Tech Maloinwazyjne. 2018 Mar;13(1):88-94
pubmed: 29643964
Wideochir Inne Tech Maloinwazyjne. 2015 Apr;10(1):30-6
pubmed: 25960790
J Thorac Dis. 2019 Apr;11(Suppl 5):S845-S850
pubmed: 31080668
World J Surg. 2017 Apr;41(4):1040-1046
pubmed: 27882418
Med Sci Monit. 2017 Mar 23;23:1421-1427
pubmed: 28331173
World J Surg Oncol. 2019 Mar 18;17(1):52
pubmed: 30885211
World J Surg. 2019 Oct;43(10):2552-2560
pubmed: 31286185